HomeCompaniesProfile

Invitris

Creating new protein-based drugs at scale 


Company Size

6 - 10 employees

Year Founded

2022


About Invitris

Invitris radically simplifies how we create novel biological drugs. Our patent-pending technology platform turns DNA into synthetic proteins and was recently featured in the Science magazine. It makes creating new drugs >10,000x more efficient at <100x lower costs of material.

Our killer application is enabling the newest generation of synthetic bacteriophages to combat antibiotic-resistant infections, which are threatening to cause more deaths than all cancers combined.

Founders & Key People

Patrick Grossmann

Patrick Grossmann

Founder, Invitris

Kilian Vogele

Kilian Vogele

Founder, Invitris

Share This Profile

More Companies

Vacations To Go Travel and Tours

We provide hassle-free, value for money, quality travel experience.

Modernbanc

Accounting software that works for you

Dex

Dex is a personal CRM that reminds you to keep in touch with the…

Tr&eacute;bol

Your back-office, on autopilot

Suger

Salesforce for Cloud marketplaces on AWS, Azure, GCP

Hotplate

Online ordering platform for independent chefs and bakers.

BEAMSTART

BEAMSTART is a global entrepreneurship community, serving as a catalyst for innovation and collaboration. With a mission to empower entrepreneurs, we offer exclusive deals with savings totaling over $1,000,000, curated news, events, and a vast investor database. Through our portal, we aim to foster a supportive ecosystem where like-minded individuals can connect and create opportunities for growth and success.

© Copyright 2025 BEAMSTART. All Rights Reserved.